ClearPoint CEO exercises options, sells 20K shares
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock.
Rhea-AI Filing Summary
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock. He exercised stock options to acquire 20,000 shares at $2.50 per share and sold 20,000 shares in an open-market transaction at a weighted average price of $19.38 per share.
Following these transactions, he holds 116,842 shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. The filing notes the exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,000 shares ($338K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
BURNETT JOSEPH
Role
CEO and President
Sold
20,000 shs ($388K)
Approx. gross sale proceeds
$388K
Approx. exercise cost
$50K
Approx. pre-tax spread
$338K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (right to buy) | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 20,000 | $2.50 | $50K |
| Sale | Common Stock | 20,000 | $19.38 | $388K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options (right to buy) — 250,000 contracts (Direct);
Common Stock — 116,842 shares (Direct);
Common Stock — 191,388 shares (Indirect, See Footnote)
Footnotes (4)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $19.15 to $19.54. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
- F4. The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017.
Key Figures
Shares sold: 20,000 shares
Sale price: $19.38 per share
Options exercised: 20,000 shares
+5 more
8 metrics
Shares sold
20,000 shares
Common Stock open-market sale on June 29, 2026
Sale price
$19.38 per share
Weighted average sale price; range $19.15–$19.54
Options exercised
20,000 shares
Common Stock acquired via stock option exercise
Exercise price
$2.50 per share
Stock options (right to buy) conversion price
Direct holdings after
116,842 shares
Common Stock held directly following transactions
Indirect holdings after
191,388 shares
Common Stock held via Joseph M. Burnett Trust
Net share change
-20,000 shares
Net of all buy/sell transactions in this Form 4
10b5-1 plan adoption date
June 11, 2025
Date written trading plan was adopted
Key Terms
Rule 10b5-1, open-market sale, Stock Options (right to buy), weighted average sales price, +2 more
6 terms
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Options (right to buy) financial
"security_title": "Stock Options (right to buy)""
weighted average sales price financial
"Represents a weighted average sales price per share."
vest financial
"The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date;"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ClearPoint Neuro (CLPT) CEO Joseph Burnett report?
Joseph Burnett reported exercising options for 20,000 ClearPoint Neuro shares at $2.50 and selling 20,000 shares at a weighted average of $19.38. These transactions were recorded as an option exercise and an open-market sale on June 29, 2026.
Was the ClearPoint Neuro (CLPT) CEO’s stock sale under a Rule 10b5-1 plan?
Yes. The Form 4 states the options exercised and shares sold were made under a written Rule 10b5-1 trading plan adopted on June 11, 2025. Such plans schedule trades in advance, making them more routine and less about short-term market timing.
What prices were involved in Joseph Burnett’s ClearPoint Neuro (CLPT) transactions?
The option exercise price was $2.50 per share for 20,000 shares. The 20,000 shares sold had a weighted average sales price of $19.38, with individual sale prices ranging from $19.15 to $19.54, as disclosed in the filing’s footnotes.
How are Joseph Burnett’s indirect ClearPoint Neuro (CLPT) holdings structured?
The Form 4 explains that 191,388 shares are held by the Joseph M. Burnett Trust dated October 20, 2022. Joseph Burnett is trustee of this trust, so these shares are reported as indirectly owned through that trust structure in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
